Brickell Biotech, Inc.
https://brickellbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Brickell Biotech, Inc.
Iksuda Aims For Best-In-Class Cancer ADCs With Toolbox Approach To Technology
Emerging Company Profile: While the UK biotech boasts a promising in-house platform technology, it believes a less restrictive approach to R&D could help it develop superior antibody-drug conjugates for cancer.
MPP Facilitates Agreements With Seven Manufacturers For COVID-19 Antiviral
The Medicines Patent Pool has facilitated sublicenses with seven manufacturers to distribute generic versions of Shionogi’s oral COVID-19 antiviral ensitrelvir across low- and middle-income countries.
Nkarta’s AML Update Disappoints, But New Conditioning Regimen Might Improve Response
An awaited update on early data for a CAR-NK therapeutic shows disappointing efficacy and duration, but a different chemotherapy conditioning regimen for lymphodepletion is showing early promise in acute myeloid leukemia.
Chinese ADC, RNA Therapy Developers Lead May/June Fundraising
Emerging companies including Bliss Biopharmaceutical, Coherent Biopharma and WestGene Biopharma lifted China biotech funding from May to mid-June.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Vical, Inc.
- Vical Incorporated (VICL)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice